We are now DEA Approved
Looking ForwardPositioned for Unprecedented Expansion
As the first publicly traded company(BGXX) in almost a century to receive federal authorization for the production of Schedule I and Schedule II plant-based drugs and APIs* for pharmaceutical applications, we are building on operational strongholds to establish and scale a reliable domestic supply chain for APIs.
Exclusive EB-5 Offering
In partnership with Asia Capital Pioneers Group (ACPG), Bright Green has launched an unparalleled USCIS EB-5 program to raise $500 million for the expansion of our high-security, advanced glass Greenhouse facilities designed for plant-based drug production at the highest standards for quality and purity.
In 2023, Bright Green’s Grants, New Mexico facility underwent a full redesign to support its next operational phase, as well as adhere to the necessary regulations and requirements for the production of plant-based drugs. With support from our new state-of-the-art facilities, we are best positioned to derive a substantial revenue share from the $10 Billion API market currently reliant on foreign imports to the U.S.
*Schedule I: Psilocybin, mescaline, peyote, ibogaine, and cannabis
Schedule II: Opium poppy, raw opium, opium extracts, powdered opium, granulated opium, tincture of opium, opium fluid extracts, poppy straw concentrate
Invested in ProgressFor Investors
Governance and Operations
Through strict oversight Bright Green continuously improves the consistency & efficiency of our operations, products, and services to make us the only domestic company capable of producing Schedule I and Schedule II plant-based drugs and APIs at scale.
Areas of Expertise And Specialization
The U.S. Opium and Cannabis Market Statistics reflect significant growth potential, driven by increasing demand for pain management medications and rising numbers of chronic disease. With the world’s most advanced agriculture ecosystem and state-of-the-art R&D facilities, Bright Green’s strategic plan align with market demands, addressing the opioid epidemic and regulatory scrutiny while meeting supply and demand at a rate more advanced than any other company on the market.
Research & Development
With an emphasis on sustainable high-tech agriculture, manufacturing, and research, Bright Green’s operational systems deliver efficacy, purity & quality. Driven by a team of medical specialists, researchers, horticultural experts, & production professionals, the consistency of our products lays the future roadmap for domestic plant-based drug production.
Bright Green CorporationOur Mission
As operations expand at our 1 million sq ft Grants, New Mexico Facility to concentrate on the research, production, manufacture, and distribution of APIs, Schedule I and Schedule II* plant-based drugs, compliance remains a key part of Bright Green’s ethos. Enabled by unique, critical licensing and operating in full alignment with federal regulations—including DEA registrations for new controlled substances—Bright Green has emerged as a leader in the US$27.97 Billion global plant-based API market.
As the sole business of this scale capable of meeting market demand, we are dedicated to securing long-term federal government contracts to establish a reliable domestic API supply chain and reduce U.S. dependency on foreign drug imports. By leveraging federal support, infrastructure funding, and strategic partnerships, Bright Green is poised to both accelerate our growth and contribute to a healthier pharmaceutical sector.
Bright Green CorporationOur Mission
As operations expand at our 1 million sq ft Grants, New Mexico Facility to concentrate on the research, production, manufacture, and distribution of APIs, Schedule I and Schedule II* plant-based drugs, compliance remains a key part of Bright Green’s ethos. Enabled by unique, critical licensing and operating in full alignment with federal regulations—including DEA registrations for new controlled substances—Bright Green has emerged as a leader in the US$27.97 Billion global plant-based API market.
As the sole business of this scale capable of meeting market demand, we are dedicated to securing long-term federal government contracts to establish a reliable domestic API supply chain and reduce U.S. dependency on foreign drug imports. By leveraging federal support, infrastructure funding, and strategic partnerships, Bright Green is poised to both accelerate our growth and contribute to a healthier pharmaceutical sector.
Terry Rafih
Executive Chairman
Check Stock Quote & Chart (BGXX)
Ready to start growing your canna-business?
Latest News and Press Releases
Ready to start growing your canna-business?
Subscribe to Our Newsletter
Subscribe to learn about the latest medical cannabis research, keep current on new resources and stay up on other news related to plant-based therapies